HPV or human papillomavirus is the most common sexually transmitted infection in women. While the current standard for the human papillomavirus (HPV) vaccine in women is a three-dose regimen, even a single dose is highly effective and provides up to 98 per cent protection, according to a study.

In a randomised controlled trial of 2,275 women in Kenya, the researchers found that even after 18 months, the bivalent vaccine was 97.5 per cent effective against two strains of HPV, and the nonavalent vaccine was 97.5 per cent effective against two strains of HPV.